Go Deep
Evonile Pharma Limited
Evonile Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,215 | 44.6 | 5.34 | 0.00 | 1,768.00 |
Evonile Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,038,100,000.0 | 905,500,000.0 | 859,000,000.0 | — |
| Net Profit | 322,100,000.0 | 252,500,000.0 | 160,900,000.0 | — |
| EPS | 13.1 | 10.2 | 6.5 | 9.8 |
Evonile Pharma Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 3,543,200,000.0 | 3,562,600,000.0 | 3,340,400,000.0 | 3,691,100,000.0 | — |
| Net Profit | 931,800,000.0 | 1,009,000,000.0 | 851,900,000.0 | 1,033,600,000.0 | — |
| EPS | 37.7 | 40.9 | 34.5 | — | — |
Evonile Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 9,782,700,000.0 | 9,478,100,000.0 | 9,249,300,000.0 | 9,829,400,000.0 | — |
| Total Liabilities | 1,604,400,000.0 | 1,628,500,000.0 | 1,801,100,000.0 | 2,072,800,000.0 | — |
| Total Equity | 8,178,300,000.0 | 7,849,600,000.0 | 7,448,200,000.0 | 7,756,600,000.0 | — |
Owes vs Owns
Evonile Pharma Limited owed ₹0.16 for every ₹1 it owned in Mar 2026, down from ₹0.21 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.16× | 0.17× | 0.19× | 0.21× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Evonile Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 67.2%Receivables 3.8%Inventory 5.5%Other assets 23.2%
How it's funded — Mar 2026
Payables 5.6%Other liabilities 10.5%Shareholders' equity 83.6%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 657.5 | 637.1 | 585.0 | 554.4 |
| Receivables | 37.0 | 40.1 | 41.5 | 36.2 |
| Inventory | 53.3 | 41.1 | 44.9 | 54.7 |
| Fixed assets (tangible) | 2.9 | 4.5 | 6.9 | 19.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.1 | 0.2 | 0.3 | 0.6 |
| Other assets | 227.4 | 224.8 | 246.4 | 317.8 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 1.6 | 3.2 | 5.1 | 17.4 |
| Payables | 54.6 | 51.5 | 61.6 | 59.7 |
| Other liabilities | 102.6 | 108.2 | 113.4 | 130.2 |
| Shareholders' equity | 817.8 | 785.0 | 744.8 | 775.7 |
| Net tangible assets | 817.8 | 785.0 | 744.8 | 775.7 |
Evonile Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 467,300,000.0 | 745,700,000.0 | 1,134,000,000.0 | 448,000,000.0 | — |
| Investing Activities | 176,300,000.0 | -33,100,000.0 | 331,300,000.0 | -1,532,500,000.0 | — |
| Financing Activities | -639,300,000.0 | -641,500,000.0 | -1,209,900,000.0 | -304,800,000.0 | — |